These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10117769)

  • 1. Multi-purpose evaluation of H2-antagonist usage.
    Gianarkis D
    Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidisciplinary education ensures successful formulary conversion.
    Barfield PS; Amerson AB
    Hosp Formul; 1991 Nov; 26 Suppl D():28-9. PubMed ID: 10136563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 5. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
    Berkowitz HS
    Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective analysis of formulary restriction demonstrates significant cost savings.
    Wetmore RW; Jennings RH
    Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiulcer therapy: an exercise in formulary management.
    Foulke GE; Siepler J
    J Clin Gastroenterol; 1990; 12 Suppl 2():S64-8. PubMed ID: 1978846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
    Dannenhoffer MA; Slaughter RL; Hunt SN
    Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of H2-receptor antagonists in children.
    Dimand RJ
    DICP; 1990 Nov; 24(11 Suppl):S42-6. PubMed ID: 2270695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
    Kowalsky SF; Hamilton RA; Figge HL
    Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T; Franko TG
    Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative evaluation of cimetidine and ranitidine.
    Zimmerman TW; Schenker S
    Ration Drug Ther; 1985 Apr; 19(4):1-7. PubMed ID: 2932770
    [No Abstract]   [Full Text] [Related]  

  • 17. Tri-hospital formulary management: a joint effort to standardize therapy and reduce costs.
    Kile DM; McGrath ME; Schindel LP
    Hosp Formul; 1987 Feb; 22(2):176, 178, 181. PubMed ID: 10280289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary.
    Calvo MV; Fruns I; Domínguez-Gil A
    Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P & T Committee interview: Establishing and maintaining a dynamic formulary.
    Rostand S; Lazarus H
    Hosp Formul; 1988 Jan; 23(1):48-53. PubMed ID: 10285373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.